Structure Therapeutics, Inc. Sponsored ADR, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Dolezal from LifeSci Capital maintained a Buy rating on the stock and has a $75.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Patrick Dolezal has given his Buy rating due to a combination of factors that highlight the potential of Structure Therapeutics, Inc. Sponsored ADR’s stock. The primary care providers (PCPs) interviewed indicated a strong prescribing trend for GLP-1 medications, which are relevant to Structure’s product offerings. These providers are responsible for a significant portion of GLP-1 prescriptions, suggesting a robust market demand.
Additionally, the discussions revealed that oral small molecules, like those developed by Structure, could be more convenient for PCPs to prescribe due to time savings and ease of use compared to injectables. This positions Structure’s products favorably in the market, especially for patients with moderate obesity or needle phobia. The financial metrics, such as the company’s cash position and manageable short interest, further support the positive outlook, making the stock an attractive buy.
In another report released on October 28, Piper Sandler also maintained a Buy rating on the stock with a $93.00 price target.